NewsBenzingaHC Wainwright & Co. riafferma l'acquisto su Alnylam Pharmaceuticals, mantiene un obiettivo di prezzo di $455 HC Wainwright & Co. riafferma l'acquisto su Alnylam Pharmaceuticals, mantiene un obiettivo di prezzo di $455 Benzinga 2026.09.21 10:34 (GMT+0) Open on Benzinga Other news Stocks Supported by a Rebound in Chipmakers and AI-Infrastructure Companies Taiwan’s President Called on Micron and Workers to Negotiate Ahead of a Possible Strike. Here’s What to Know. Rocket Lab's Biggest Technological Advantage Is Fast Becoming Its Biggest Problem Why Is IREN Stock Surging Monday? Venture Global Stock Just Secured a Data Center Win. How to Play It Here. PrimeXBT Launches 14-Day VIP Welcome Offer, Cutting Trading Costs for All New Users
Taiwan’s President Called on Micron and Workers to Negotiate Ahead of a Possible Strike. Here’s What to Know.
